While accessibility and affordability of insulin pose significant challenges in India, particularly in tier 2, tier 3, and tier 4 cities, 377 Indian experts opined that the interchangeable biosimilar insulin glargine is equally efficacious and safe to the reference insulin glargine and a viable solution which could greatly enhance the accessibility and affordability of insulin, a crucial medicine for managing diabetes, in real-world clinical practice. Here, INS is linked to diabetes mellitus.